This inventor holds 1 USPTO granted patent. Top assignee: National Dong Hwa University. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Kuei-Hung Lai: Innovator in Cancer Treatment
Introduction
Kuei-Hung Lai is a notable inventor based in Hualien, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. His innovative work focuses on the extraction and application of specific compounds that have the potential to inhibit cancer cell growth.
Latest Patents
Kuei-Hung Lai holds a patent for a groundbreaking invention titled "Scalarane sesterterpenoid, pharmaceutical composition and topoisomerase II and Hsp90 inhibitor for treating cancer, and use and preparation method thereof." This patent discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from specific sponge species. The compounds of formula (I) are designed to act as anticancer agents, targeting topoisomerase II and Hsp90, thereby providing a pharmaceutical composition for cancer treatment. He has 1 patent to his name.
Career Highlights
Kuei-Hung Lai is affiliated with National Dong Hwa University, where he continues to engage in research and development in the pharmaceutical field. His work is characterized by a commitment to advancing cancer treatment methodologies through innovative approaches.
Collaborations
Kuei-Hung Lai collaborates with esteemed colleagues, including Mei-Chin Lu and Ping-Jyun Sung, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their work in the field of cancer treatment.
Conclusion
Kuei-Hung Lai's contributions to cancer treatment through his innovative patent highlight the importance of research in pharmaceuticals. His work exemplifies the potential of scientific advancements to improve health outcomes for patients battling cancer.